Andreas Schulte-Mecklenbeck Selected Research

Andreas Schulte-Mecklenbeck Research Topics

Disease

13	Multiple Sclerosis 01/2023 - 02/2016
7	Relapsing-Remitting Multiple Sclerosis 11/2021 - 12/2016
3	Disease Progression 03/2024 - 01/2018
2	Autoimmune Diseases of the Nervous System 01/2023 - 07/2017
2	Neoplasms (Cancer) 01/2022 - 07/2018
2	Primary angiitis of the central nervous system 01/2018 - 01/2018
1	Isaacs Syndrome (Neuromyotonia) 01/2023
1	Glioblastoma (Glioblastoma Multiforme) 01/2022
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022
1	Infections 01/2022
1	Psychotic Disorders (Schizoaffective Disorder) 12/2021
1	Autoimmune limbic encephalitis 12/2021
1	Ataxia (Dyssynergia) 02/2021
1	Brain Diseases (Brain Disorder) 02/2021
1	Bilateral Hearing Loss 02/2021
1	Pain (Aches) 02/2021
1	Paraparesis 02/2021
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2021
1	Progressive Multifocal Leukoencephalopathy 01/2021
1	Hippocampal Sclerosis 10/2020
1	Limbic Encephalitis (Paraneoplastic Limbic Encephalitis) 10/2020
1	Yellow Fever 11/2019
1	Cognitive Dysfunction 11/2019
1	Epilepsy (Aura) 11/2019
1	Liver Failure 01/2019
1	Autoimmune Diseases (Autoimmune Disease) 12/2018
1	Vitiligo 12/2018
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 07/2018
1	Anti-N-Methyl-D-Aspartate Receptor Encephalitis 07/2017
1	Herpes Simplex 07/2017
1	Central Nervous System Diseases (CNS Diseases) 01/2017
1	Nervous System Diseases (Neurological Disorders) 01/2017
1	Cerebellar Ataxia (Dysmetria) 01/2017
1	Multiple System Atrophy 01/2017
1	Neurocognitive Disorders (Clerambault Syndrome) 09/2015
1	HIV Infections (HIV Infection) 09/2015

Drug/Important Bio-Agent (IBA)

4	AutoantibodiesIBA 01/2023 - 01/2017
4	Natalizumab (Tysabri)FDA Link 01/2023 - 01/2018
4	AntibodiesIBA 01/2022 - 07/2018
4	Alemtuzumab (Campath)FDA Link 01/2022 - 12/2016
3	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2018
2	InterferonsIBA 03/2024 - 12/2018
2	N-acetyltalosaminuronic acid (NAT)IBA 01/2023 - 01/2018
2	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 12/2021 - 10/2020
2	Protein Isoforms (Isoforms)IBA 12/2021 - 10/2020
2	Dimethyl FumarateIBA 11/2021 - 02/2016
2	HLA-DR Antigens (HLA-DR)IBA 01/2021 - 09/2015
2	Fingolimod Hydrochloride (FTY720)FDA Link 11/2019 - 01/2018
2	Immunoglobulins (Immunoglobulin)IBA 07/2018 - 01/2018
1	Cladribine FDA LinkGeneric 01/2023
1	Integrin alpha4beta1 (VLA-4)IBA 11/2022
1	Methylprednisolone FDA LinkGeneric 09/2022
1	SteroidsIBA 09/2022
1	Tryptophan (L-Tryptophan)FDA Link 09/2022
1	Interleukin-2 (IL2)IBA 01/2022
1	KIR ReceptorsIBA 01/2022
1	SuspensionsIBA 01/2022
1	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2021
1	Methadone (Dolophine)FDA LinkGeneric 02/2021
1	Opioid Analgesics (Opioids)IBA 02/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	LigandsIBA 11/2019
1	Daclizumab (Zenapax)FDA Link 01/2019
1	teriflunomideIBA 01/2019
1	HLA Antigens (Human Leukocyte Antigens)IBA 12/2018
1	CytokinesIBA 12/2018
1	N 30IBA 12/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2018
1	AntigensIBA 07/2018
1	Amyloid beta-PeptidesIBA 01/2018
1	ImmunosorbentsIBA 01/2018
1	EnzymesIBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 07/2017
1	Rituximab (Mabthera)FDA Link 07/2017
1	neurochondrinIBA 01/2017
1	Interleukin-2 Receptors (IL 2 Receptor)IBA 05/2016

Therapy/Procedure

6	Therapeutics 03/2024 - 01/2017
1	Immunotherapy 01/2023
1	Aftercare (After-Treatment) 12/2018
1	Withholding Treatment 01/2018
1	Highly Active Antiretroviral Therapy (HAART) 09/2015